Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Dr. Ostertag on Emerging CAR T Product for Myeloma

August 29th 2018

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

FDA Approval Sought for Once-Weekly Carfilzomib Regimen in Myeloma

August 27th 2018

A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Expert Highlights Promising Multiple Myeloma Data

August 24th 2018

Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.

FDA Grants Elotuzumab Triplet Priority Review for Myeloma

August 23rd 2018

The FDA has granted a priority review to a supplemental biologics license application for elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Advances Could Lead to Curative Strategies in Myeloma

August 21st 2018

Nikhil C. Munshi, MD, discusses the current treatment landscape of myeloma and potential next steps to further advancing care.

Dr. Holstein Discusses Triplets and Quadruplets in Myeloma

August 17th 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the use of triplets and quadruplets in the treatment of patients with multiple myeloma.

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

August 16th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

August 8th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Patient-Reported Outcomes With Stem Cell Transplant Signal Progress in Myeloma

August 8th 2018

Noa Biran, MD, discusses patient-reported outcomes following autologous stem cell transplant in patients with myeloma.

Selinexor FDA Submission Completed for Multiple Myeloma

August 8th 2018

A rolling submission of an FDA new drug application has been completed for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics.

Emerging Approaches Offer Hope in Heavily Pretreated Myeloma

August 7th 2018

Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

bb2121 Continues to Show Potential in Multiple Myeloma

August 2nd 2018

Noopur Raje, MD, discusses the updated results from the CRB-401 trial and next steps with bb2121 in multiple myeloma.

Dr. Kambhampati on Updates in Myeloma from the 2018 ASCO Annual Meeting

August 2nd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

EU Panel Backs Frontline Daratumumab/VMP Combo for Multiple Myeloma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Holstein Discusses Induction Therapy for Multiple Myeloma

July 23rd 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses induction therapy for the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma

July 20th 2018

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

NEXT PAGE
PREVIOUS PAGE